Advertisement
Advertisement
BVS
Bioventus Inc. Class A Common Stock
10.50
USDSponsored
-0.15
-1.41%
May 08, 15:59 UTC -4
Closed
Pre-Market
10.46
-0.04
-0.43%
BVS Earnings Reports
Positive Surprise Ratio
BVS beat 16 of 22 last estimates.
73%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$158.23M
/$0.22
Implied change from Q1 26 (Revenue/ EPS)
+19.79%
/+46.67%
Implied change from Q2 25 (Revenue/ EPS)
+7.16%
/+4.76%
Bioventus Inc. Class A Common Stock earnings per share and revenue
On May 06, 2026, BVS reported earnings of 0.15 USD per share (EPS) for Q1 26, beating the estimate of 0.09 USD, resulting in a 52.28% surprise. Revenue reached 132.09 million, compared to an expected 131.15 million, with a 0.72% difference. The market reacted with a +2.25% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of 0.22 USD, with revenue projected to reach 158.23 million USD, implying an increase of 46.67% EPS, and increase of 19.79% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Bioventus Inc. Class A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Bioventus Inc. Class A Common Stock reported EPS of $0.15, beating estimates by 52.28%, and revenue of $132.09M, 0.72% above expectations.
How did the market react to Bioventus Inc. Class A Common Stock's Q1 2026 earnings?
The stock price moved up 2.25%, changed from $10.68 before the earnings release to $10.92 the day after.
When is Bioventus Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for Bioventus Inc. Class A Common Stock's next earnings report?
Based on 4
analysts, Bioventus Inc. Class A Common Stock is expected to report EPS of $0.22 and revenue of $158.23M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement